Member Info for amones

Thanks to Davey and JatW for keeping this board alive. Let’s hope for much better prospects in 2020.

The sociopolitical scene at HK is still not settled as per today’s news.

Davey, in your opinion why not a listing at Shanghai exchange? Or, even use the newly created London- Shanghai Stock exchange link. This would allow investors from Asia to buy HCM shares. The latter would make life easy for us, good old British investors! Hope our CEO will be able to say few words about this opportunity at the forthcoming Deutsche Bank conference.

Good news. Thanks for sharing, Davey.

(However, London market still not willing to wake up!! In the ‘good old days’, the sp would have jumped markedly in response to such news items)

HCM should exploit this opportunity to garner interest among Asian investors. This company is valued mere 2.8 Billions USD. It will be a great opportunity for investors from Asia to buy at these levels.

In the mean while, quite sadly, it appears to behave like day traders’ delight :(

A fresh news of collaboration with a major pharmaceutical or approval of NDA for a new drug is what’s going to impress Asian investors. Any new listing either at Shanghai or HK should be timed to coincide with such major news.
Or, the company might wish to move to main platform at LSE so as to make use of the London- Shanghai link.

Totally agree with the observation and opinion of tacly in the “Headwinds” thread. Many members of this board agree to the point that getting Chinese/Asian investors on board is the need of the hour for this company’s financial prospects. Listing on NYSE did bring some positive momentum. But, as Davey has mentioned, US investors prefer to take a punt in smaller biotechs which are going to be taken over by bigger MNCs. Doubtful if HCM falls in to that category. It’s not likely that ADR share price can attain last year’s peaks in the near future due to the trump lead political issues.

As far as listing on Shanghai stock exchange, the board should make sure it is properly done. Otherwise, Chi-Med would end up as one of the dozens of smaller pharma companies already listed there. Maintaining its LSE listing, UK /Chinese directors providing leadership and guidance will help to attract investors from China and Hong Kong. British standards are greatly appreciated in China. The fact that “it is also listed in London” could be helpful in creating a better sentiment among prospective Chinese and Asian investors. Hope it happens soon.

Davey,
Let us keep our fingers crossed.
If you happen to communicate with the company regarding this issue, please do inform other members here.

Nice to see the updated pipeline.
But, it is not helpful enough to stop the share price moving in the negative direction. A similar update and news from last week about the collaboration with Innovent, would have propelled share price sharply upwards, in normal market conditions. This share needs new buyers from Asia, particularly China. After all, HCM is an Asian company.

Davey,
How old is this assessment by Edison group?
If you are still buying, appreciate your confidence in this company. Especially, during the continuous drop in sp. Sincerely hope the directors can match your confidence. Good luck.

Davey, with in the last year, there was news (?Times) about the newly created link between London and Shanghai stock exchanges allowing investors dealing in either of the exchanges to buy/ sell shares listed in the other exchange. ( someone with better understanding about this is most welcome to explain). As Hong Kong listing isn’t going to materialise soon, the ‘ link between Shanghai and London’ could be useful for China based investors to invest in their own country’s company.

Some time ago, I had asked few questions on this board. I don’t remember seeing a definitive answer.
HCM shares have fallen more than half of the peak price (£5.9 December 2017). I feel like asking the same questions again.

Other than the board of directors, are there any China based financial institutions, fund managers and private investors who have invested in chi-med? Does this company get any coverage in Chinese financial news sectors? Being the first ever Chinese pharma to develop and market a cancer medicine (and few more in the pipeline), does its existence known to the Chinese rich and upper class investors?

Davey, thanks for posting this encouraging piece of information during these discouraging days, at least, as far as share price is concerned.

I wonder if any other pharma company has ever experienced this kind of poor market valuation at a time while presenting and publishing successful phase 3 results and applying to market a new anti malignancy medication.
In addition, this company also has few more agents for cancer therapy and autoimmune disorders under various stages of research and development.
Totally, unbelievable! Is there a similar example in pharma history, anybody?

The directors should buy to bring back the confidence.

RNS about HMPL-523, a spleen tyrosine kinase inhibitor in phase 1 study in Idiopathic thrombocytopaenic purpura is fantastic. HCM is showing its ability to penetrate autoimmune disorder therapeutics. This is proving that Chi med is not limited to anti malignancy therapeutics field. One successful Autoimmune disorder therapy will open HCM to a major pharmaceutical market. It is very encouraging to see that HMPL-523, a spleen tyrosine kinase is already being attached to haematological malignancies like leukaemia as well.
After long period of lull, it’s been an encouraging day.

Thanks Warwis for posting this information.
That’s very interesting indeed. After weeks of uneasiness due to the untidy, untimely and poorly managed secondary offering, this IC article (GSK and J&J looking for innovative firms) might help to bring some interest, if not cheers, among investors.
It could be just a guess work to predict such takeover. However, it is in the investor’s chronicle. The present market valuation of chi med could appear very attractive for the assets ( drug candidates in the pipeline, research facilities, scientists) it holds. But, will the present major share holders give it away cheaply, after having developing the company from the scratches for more than 15 years?

HHHL trying to sell 12 million ADRs at a ‘reduced ‘ price of $24. Who would buy at that price when the actual SP on NYSE is less than $22 ?
Or, has Morgan Stanley got confirmed buyers on their books?
Or, would the sale be withdrawn?
Interesting days ahead.

This is a secondary offer means majority shareholder is offering part of their existing holding. Not new shares and no reduction of market valuation as the total number of shares in circulation remains unchanged. HHHL are reducing their holding from some 63% to 53%, if I am correct. Intentions of reduction in their holding was announced few weeks ago.

With the high standards of trading regulations, LSE listed stocks should be attractive to Chinese investors. HCM being a China based company with a fantastic track record, great management headed by very good CEO and an attractive pipeline, we can expect good days ahead. Perhaps, Chi Med should consider listing on Shanghai SE and create a similar ‘parallel’ valuation it has between AIM listed shares and NYSE listed HCM ADRs. Am I expecting too much??;)

Seen a message on another bb. As per the new link, started from today, between Shanghai stock market and London stock market, investors in UK and China can buy shares in each other’s stock exchanges. Good news for chi med.

Appears the surufatinib news has made no impact on ADR price so far, today. Perhaps, we may have to wait until the NDA application gets approved before seeing any improvement in HCM share price!

Thanks jatW and others. I have been buying HCM for more than 7 years. Never had to pay any stamp duty as HCM is an AIM share. Bit surprised to see this morning’s buy order quote showed stamp duty of 0.5%. It made me to wonder if HCM has moved out of AIM.